Liang Legal Group, PLLC
Quinoxaline compounds as type III receptor tyrosine kinase inhibitors
A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases. 
Development Center for Biotechnology
A A C A C A C C A A C C C C C C C C C
A61P A61P C07D A61P C07D A61P C07D C07D A61P A61P C07D C07D C07D C07D C07D C07D C07D C07D C07D
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Shao-Zheng Hung-Kai Hung-Jyun Shian-Yi Chen-Hsuan Chu-Bin
Peng Chen Huang Chiou Ho Liao